Daily Cosmetic Research Analysis
Three papers stand out today: an MRI-informed mechanobiological model that predicts patient-specific cosmetic deformation after breast-conserving surgery, a microfluidics-based sunscreen microcapsule platform that boosts SPF while halving skin permeation of an organic UV filter, and a newly established imatinib-resistant DFSP cell line enabling drug discovery beyond current standards. Together, they advance predictive surgery planning, safety-by-design cosmetic formulation, and preclinical oncol
Summary
Three papers stand out today: an MRI-informed mechanobiological model that predicts patient-specific cosmetic deformation after breast-conserving surgery, a microfluidics-based sunscreen microcapsule platform that boosts SPF while halving skin permeation of an organic UV filter, and a newly established imatinib-resistant DFSP cell line enabling drug discovery beyond current standards. Together, they advance predictive surgery planning, safety-by-design cosmetic formulation, and preclinical oncology.
Research Themes
- Personalized prediction of cosmetic outcomes after surgery
- Safety-by-design sunscreen delivery via microfluidics
- Preclinical models of drug resistance in cutaneous sarcoma
Selected Articles
1. Computational Modeling of Patient-Specific Healing and Deformation Outcomes Following Breast-Conserving Surgery Based on MRI Data.
An MRI-informed, multiscale mechanobiological model simulated post-BCS healing and trained surrogate models to rapidly predict breast surface deformation. It identified breast density, cavity volume, breast volume, and cavity depth as key drivers of postoperative contraction and cosmetic asymmetry.
Impact: Provides a personalized predictive framework for cosmetic outcomes after oncologic breast surgery, a long-standing unmet need impacting quality of life. It bridges imaging, biomechanics, and machine learning for actionable preoperative counseling.
Clinical Implications: Can inform surgical planning (incision, cavity management, oncoplastic techniques) and patient counseling by predicting likely deformation trajectories, potentially reducing revision surgeries and improving satisfaction.
Key Findings
- Integrated preoperative MRI-derived geometries into finite element simulations of post-BCS healing.
- Gaussian process surrogate models enabled rapid prediction of breast surface deformation.
- Breast density, cavity volume, breast volume, and cavity depth were key predictors of contraction and deformation.
Methodological Strengths
- Multiscale mechanobiological modeling coupled with patient-specific MRI geometry.
- Use of Gaussian process surrogates for efficient, generalizable predictions across patient profiles.
Limitations
- Lack of prospective clinical validation correlating predictions with longitudinal measured outcomes.
- Model assumptions may simplify complex wound biology and tissue heterogeneity.
Future Directions: Prospective validation against longitudinal 3D surface imaging; integration of radiotherapy effects and oncoplastic techniques; deployment as a clinical decision-support tool.
PURPOSE: Breast-conserving surgery (BCS) is the standard of care for early-stage breast cancer, offering recurrence and survival rates comparable to mastectomy while preserving healthy breast tissue. However, surgical cavity healing post-BCS often leads to highly variable tissue remodeling, including scar tissue formation and contracture, leading to visible breast deformation or asymmetry. These outcomes significantly impact patient quality of life but are difficult to predict due to the complex interplay between biologic healing processes and individual patient variability. To address this challenge, we extended our calibrated computational mechanobiological model of post-BCS healing by incorporating diagnostic imaging data to evaluate how patient-specific breast and tumor characteristics influence healing trajectories and deformation. METHODS: The model captured multi-scale biologic and biomechanical processes, including fibroblast activity, collagen remodeling, and nonlinear tissue mechanics, to simulate time-dependent tissue remodeling. Patient-specific breast and tumor geometries from preoperative magnetic resonance imaging (MRI) were integrated into finite element simulations of cavity healing, whose outputs trained Gaussian process surrogate models for rapid prediction of healing dynamics and breast surface deformation across diverse patient profiles. RESULTS: These models revealed how factors including breast density, cavity volume, breast volume, and cavity depth influence post-surgical cavity contraction and measures of breast surface deformation. CONCLUSION: This framework has the potential to provide a personalized, predictive tool for surgical planning and decision-making, enabling clinicians and patients to anticipate healing trajectories and cosmetic outcomes, with the goal of optimizing surgical results and enhancing patient quality of life.
2. Microfluidics preparation of poly(lactic acid) microcapsules encapsulated with octyl methoxycinnamate for sunscreen application.
Microfluidics produced uniform PLA microcapsules encapsulating OMC with >95% encapsulation and >22% loading, yielding a 113% SPF increase and significantly enhanced UV stability, while reducing OMC skin permeation by 50%. This platform addresses efficacy-safety tradeoffs in sunscreens.
Impact: Demonstrates a controllable, scalable route to improve sun protection while minimizing systemic exposure to chemical UV filters, aligning with regulatory and consumer safety priorities.
Clinical Implications: Supports development of higher-SPF, more photostable sunscreens with lower systemic absorption risk; may inform reformulation of existing products and future clinical safety testing.
Key Findings
- Microfluidics enabled 10–38 μm uniform PLA microcapsules with encapsulation efficiency >95% and loading capacity >22%.
- Formulations with OMC microcapsules increased SPF by 113% and improved UV stability versus conventional methods.
- Skin permeation of OMC decreased by 50%, indicating reduced systemic exposure risk.
Methodological Strengths
- Head-to-head comparison with homogenization highlighting monodispersity and performance gains.
- Comprehensive characterization linking residence time to morphology, EE/LC, SPF, UV stability, and permeation.
Limitations
- In vitro/ex vivo assessments without human clinical testing.
- Focused on a single organic UV filter (OMC) and one polymer matrix; generalizability requires testing other actives and vehicles.
Future Directions: Scale-up studies in continuous-flow microreactors, evaluation with multiple UV filters and blends, and controlled clinical studies assessing SPF, photostability, and systemic exposure.
OBJECTIVE: The systemic absorption of active ingredients in commercial sunscreens has raised safety concerns. This has created a need for advanced delivery systems that can enhance efficacy while minimising skin penetration. A promising solution is the encapsulation of sunscreen agents within microcapsules. The objective of this study is to demonstrate a simple and controllable method based on microfluidics for the preparation of sunscreen microcapsules with high ultraviolet absorption, good thermal stability, enhanced monodispersity and improved UV absorption performance. METHODS: A microfluidics-assisted method was employed to encapsulate a typical chemical UV filter, octyl methoxycinnamate (OMC), within biodegradable poly(lactic acid) (PLA) microcapsules using a commercial Corning Advanced-Flow microreactor. The effects of residence time on the morphology, size, encapsulation efficiency (EE) and loading capacity (LC) of the microcapsules were examined through comprehensive characterisation. Sun protection factor (SPF), UV stability and skin penetration of the microcapsules were also assessed, with release kinetics investigated by different models. RESULTS: The microfluidics-prepared microcapsules exhibited a uniform spherical morphology with adjustable sizes (10-38 μm), high encapsulation efficiency (>95%) and loading capacity (>22%). Compared to microcapsules prepared by the homogenisation method, the microfluidics-prepared ones displayed improved monodispersity and UV absorption performance. These improvements arise from microfluidics' precise control over droplet formation and narrow residence time distribution. Moreover, formulations containing OMC-loaded microcapsules achieved a 113% increase in SPF and significantly enhanced UV stability, along with a 50% reduction in skin permeation of OMC. CONCLUSIONS: This study highlights the significant potential of microfluidics encapsulation for producing uniform sunscreen microcapsules with enhanced efficacy, stability and safety. By minimising systemic absorption while improving UV protection, this approach meets growing regulatory and consumer demands for safer, high-performance sunscreen formulations. These findings offer valuable insights for advancing next-generation cosmetic products. OBJECTIF: L'absorption systémique des principes actifs dans les écrans solaires commerciaux a soulevé une inquiétude en ce qui concerne la sécurité d'emploi. De ce fait, des systèmes de distribution avancés pouvant améliorer l'efficacité tout en réduisant la pénétration dans la peau sont nécessaires. L'encapsulation d'agents de protection solaire dans des microcapsules est une solution prometteuse. L'objectif de cette étude est de présenter une méthode simple et contrôlable utilisant la microfluidique pour préparer des microcapsules de crème solaire avec une absorption ultraviolette élevée, une bonne stabilité thermique, une meilleure monodispersion et de meilleures performances d'absorption des UV. MÉTHODES: Une méthode assistée par microfluidique a été employée pour encapsuler un filtre UV chimique typique, le méthoxycinnamate d'octyle (OMC), dans des microcapsules en (acide) poly(lactique) (APL) biodégradables à l'aide d'un microréacteur commercial Corning Advanced‐Flow. Une caractérisation complète a permis d'examiner les effets du temps de résidence sur la morphologie, la taille, l'efficacité de l'encapsulation (EE) et la capacité de charge (CC) des microcapsules. Le facteur de protection solaire (FPS), la stabilité UV et la pénétration cutanée des microcapsules ont également été évalués, avec une cinétique de libération étudiée par différents modèles. RÉSULTATS: Les microcapsules préparées par microfluidique présentaient une morphologie sphérique uniforme avec des tailles ajustables (10 à 38 μm), une efficacité d'encapsulation élevée (>95%) et une capacité de charge élevée (>22%). Par rapport aux microcapsules préparées par méthode d'homogénéisation, celles préparées par microfluidique présentaient une amélioration de la monodispersion et de l'absorption des UV. Ces améliorations sont dues au contrôle précis de la microfluidique sur la formation des gouttelettes et de la distribution étroite du temps de résidence. De plus, les formulations contenant des microcapsules chargées d'OMC ont permis une augmentation de 113% du FPS et une amélioration significative de la stabilité aux UV, ainsi qu'une réduction de 50% de la perméation cutanée de l'OMC. CONCLUSIONS: Cette étude met en évidence le potentiel significatif de l'encapsulation par microfluidique pour produire des microcapsules de crème solaire uniformes avec une efficacité, une stabilité et une sécurité d'emploi améliorées. En réduisant l'absorption systémique tout en améliorant la protection contre les UV, cette approche répond aux exigences croissantes des clients et des réglementations en matière de formulations de crème solaire plus sûres et haute performance. Ces résultats offrent des informations précieuses pour faire progresser les produits cosmétiques de nouvelle génération.
3. Establishment and characterization of a novel imatinib-resistant dermatofibrosarcoma protuberans cell line, DFSP-DPH1.
The authors established DFSP-DPH1, an imatinib-resistant DFSP cell line with a unique COL1A1 exon 46–PDGFB exon 2 fusion breakpoint, retaining diagnostic markers and aggressive phenotypes. Drug screening across 48 PDGFR inhibitors identified agents with greater efficacy than imatinib, enabling resistance biology and therapy development.
Impact: Provides a much-needed, well-characterized preclinical DFSP model with a novel fusion breakpoint and confirmed imatinib resistance to accelerate translational research.
Clinical Implications: Enables preclinical testing of alternative PDGFR inhibitors and combination strategies for imatinib-resistant DFSP, informing future clinical trials.
Key Findings
- Established DFSP-DPH1 retaining CD34 and vimentin expression with factor XIIIa negativity and fibroblast-like morphology.
- Identified a novel COL1A1 exon 46–PDGFB exon 2 fusion breakpoint not previously reported in DFSP cell lines.
- Confirmed imatinib resistance and found multiple PDGFR inhibitors outperforming imatinib in drug screening.
- Transcriptomic profiling showed dominance of COL1A1::PDGFB fusion and enrichment of cancer/viral/neuroactive pathways.
Methodological Strengths
- Comprehensive validation including STR profiling, immunophenotyping, and Sanger sequencing of fusion breakpoint.
- Functional assays (3D spheroids, migration/invasion) and broad inhibitor screening (n=48) provide translationally relevant phenotyping.
Limitations
- Derived from a single patient; external validity across DFSP subtypes remains uncertain.
- Lacks in vivo validation and tumor microenvironment interactions.
Future Directions: Establish additional resistant lines, perform in vivo xenograft validation, and explore combination therapies targeting PDGFR signaling and downstream pathways.
Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive cutaneous sarcoma characterized by high recurrence rates and the development of resistance to imatinib. The scarcity of preclinical models hinders research into DFSP pathogenesis and the development of novel therapeutic strategies. In this study, we established and characterized a novel DFSP cell line, designated DFSP-DPH1, derived from a 47-year-old male patient with an abdominal tumor. Comprehensive characterization confirmed that DFSP-DPH1 retains key features of the original tumor, including the fibroblast-like spindle morphology and expression of diagnostic markers CD34 and vimentin, with absence of factor XIIIa. Short tandem repeat profiling confirmed the cell line's origin and excluded cross-contamination. Sanger sequencing revealed a COL1A1 exon 46-PDGFB exon 2 fusion transcript, a breakpoint not previously reported in established DFSP cell lines. Functionally, DFSP-DPH1 exhibits robust proliferative capacity, forms three-dimensional spheroids under anchorage-independent conditions, and demonstrates significant migratory and invasive capabilities. Drug sensitivity screening of a panel of 48 PDGFR inhibitors confirmed its resistance to imatinib and identified several compounds with superior efficacy compared to imatinib. Transcriptomic analysis confirmed the dominance of the COL1A1::PDGFB fusion transcript and revealed enrichment of pathways related to cancer, viral infection, and neuroactive ligand-receptor interaction. This novel imatinib-resistant DFSP cell line, DFSP-DPH1 provides a valuable preclinical model for investigating the molecular mechanisms underlying DFSP pathogenesis, drug resistance, and tumor progression, and for developing and evaluating novel therapeutic strategies.